Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2022-10-18 00:00:00 ET · period of report 2022-10-14 · accession 0001883850-22-000082 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-10-18 | 2022-10-14 | REGN | Landry Robert E | EVP Fin CFO | M - OptEx | $381.92 | +1,500 | 30.2K | +5% | +$572.9K |
| D | 2022-10-18 | 2022-10-17 | REGN | Landry Robert E | EVP Fin CFO | S - Sale+OE | $739.50 | -358 | 28.7K | -1% | -$264.7K |
| D | 2022-10-18 | 2022-10-14 | REGN | Landry Robert E | EVP Fin CFO | F - Tax | $743.78 | -1,142 | 29.1K | -4% | -$849.4K |
| D | 2022-10-18 | 2022-10-14 | REGN | Landry Robert E | EVP Fin CFO | M - OptEx | $0.00 | -1,500 | 11.3K | -12% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-10-14 | M | A | 1,500 | $381.92 | 30,244 | D | — | — | |
| 2 | Common | Common Stock | 2022-10-17 | S | D | 358 | $739.50 | 28,744 | D | — | — | |
| 3 | Common | Common Stock | 2022-10-14 | F | D | 1,142 | $743.78 | 29,102 | D | — | — | |
| 4 | Derivative | Non-Qualified Stock Option (right to buy) | 2022-10-14 | M | D | 1,500 | $0.00 | 11,300 | D | $381.92 · — to 2026-12-16 | 1,500 Common Stock | (F2) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |